{"filing":{"accession_number":"0001193125-26-363695","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-18","primary_document":"d152818d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526363695/d152818d8k.htm"},"events":[{"id":29217,"run_id":26731,"accession_number":"0001193125-26-363695","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses both a departure (Justin Trojanowski resigning as Principal Financial Officer effective September 1, 2026) and an appointment (Nicholas Rossettos appointed as Chief Financial Officer and Principal Financial and Accounting Officer effective the same date). While both events occur, the principal disclosed action centers on the appointment of Rossettos to the critical CFO/Principal Accounting Officer role, with detailed background on his 30+ years of experience in biopharmaceutical finance. The appointment of a new CFO is material to investors assessing financial leadership and reporting integrity.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31407,"accession_number":"0001193125-26-363695","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a departure (Justin Trojanowski resigning as Principal Financial Officer effective September 1, 2026) and an appointment (Nicholas Rossettos appointed as Chief Financial Officer and Principal Financial and Accounting Officer effective the same date). While both events occur, the principal disclosed action centers on the appointment of Rossettos to the critical CFO/Principal Accounting Officer role, with detailed background on his 30+ years of experience in biopharmaceutical finance. The appointment of a new CFO is material to investors assessing financial leadership and reporting integrity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:44:51.574774+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31407,"accession_number":"0001193125-26-363695","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a departure (Justin Trojanowski resigning as Principal Financial Officer effective September 1, 2026) and an appointment (Nicholas Rossettos appointed as Chief Financial Officer and Principal Financial and Accounting Officer effective the same date). While both events occur, the principal disclosed action centers on the appointment of Rossettos to the critical CFO/Principal Accounting Officer role, with detailed background on his 30+ years of experience in biopharmaceutical finance. The appointment of a new CFO is material to investors assessing financial leadership and reporting integrity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:44:51.574774+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-08-24"}]}